Impact of a Fixed Combination of Clindamycin Phosphate 1.2%–Benzoyl Peroxide 2.5% Aqueous Gel on Health-Related Quality of Life in Moderate to Severe Acne Vulgaris
Webster G, Thiboutot DM, Chen DM, Merikle E
![](/sites/all/themes/custom/medstat_cutis/img/logo.png)
The acne-specific quality of life (Acne-QoL) questionnaire was developed to measure the impact of facial acne across 4 domains (acne symptoms, role-emotional, self-perception, role-social) of health-related quality of life (HRQL). This analysis assessed the impact of clindamycin phosphate 1.2%–benzoyl peroxide 2.5% (clindamycin–BPO 2.5%) gel on HRQL in a combined study population (N=2813) of participants with moderate to severe acne vulgaris. Although the results presented within do not include factors of study and study-by-treatment interaction, analyses were performed to confirm that the results were consistent across the 2 identical, double-blind, randomized studies and within each treatment group across studies to justify pooling the data from both studies.
The Acne-QoL questionnaire was administered at baseline and at the end of treatment (week 12). Treatment with clindamycin–BPO 2.5% gel significantly improved participant-reported HRQL across all 4 domains compared with individual active ingredients and vehicle (P